Shilpa Stumbles On Lenvima Challenge And Faces Wait Until 2036
Indian Firm Had Challenged Eisai’s US Patent For ‘Highly Pure Lenvatinib Mesylate’
Generic competition to Eisai’s oral-dose blockbuster cancer therapy Lenvima is set to materialize in the US in 2030 – however, for now, that won’t be from ANDA filer Shilpa Medicare.
